Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food Effects Study of HRX0701 in Healthy Subjects
NCT05415644Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of retagliptin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Peak Plasma Concentration (Cmax) in postprandial state, Area Under the Curve from time zero to last measurable concentration (AUC0-t) in postprandial state and 5 more. Started Jul 2022; status: completed.
02
Drugs
retagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05415644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05415644.